Pradofloxacin

Pradofloxacin is a third-generation enhanced spectrum veterinary antibiotic belonging to the fluoroquinolone class. It functions by inhibiting bacterial DNA gyrase and topoisomerase IV enzymes, which are vital for bacterial DNA replication, transcription, and recombination, ultimately leading to rapid bacterial cell death. Pradofloxacin demonstrates broad-spectrum activity against various Gram-positive and Gram-negative bacteria, including anaerobes. Initially developed by Bayer HealthCare AG, Animal Health GmBH, and later associated with Elanco Animal Health GmbH following an acquisition, it received European Commission approval in April 2011 for treating bacterial infections in dogs and cats. In the United States, it is indicated for specific respiratory diseases in cattle and swine, and for skin, urinary tract, and respiratory tract infections in cats.

Brand names

VerafloxPradalex

Other names

pradofloxacin injection